Newly released results from the Lucentis treatment studies show just how successful the macular degeneration drug is.

The latest, two-year information from the Lucentis treatment studies revealed positive new findings about the success of the drug.

Click here to watch a Lucentis treatment animation

Lucentis treatment is used to treat age-related macular degeneration (AMD), a leading cause of blindness in people over 50 years of age. Lucentis works by inhibiting the growth of the abnormal blood vessels that cause AMD. It is also used to treat swelling of the macula due to AMD. The goal of treatment is to prevent further loss of vision.

The AMD medication is administered by an injection into your eye as needed at regular intervals (about every four or five weeks) – your ophthalmologist will tell you how often you will need to receive the injection.

The study demonstrated that the patients who’s visual acuity improved from the macular degeneration therapy, maintained their improved vision at year two.

Since age-related macular degeneration is an ongoing, progressive eye disease, the news that vision improvements from the treatments last at least two years is exciting.

The study also showed that 90% of patients treated with 0.3mg and 0.5mg of this powerful AMD drug either maintained or improved vision and up to 41% of patients had improved vision.

Related information:

New Lucentis v. Stroke Information

Interim Lucentis treatment study data showed that, at six months into the study, Lucentis use in stroke patients may lead to an increased risk of stroke.

However, once the final study was complete, results showed that there was no associated risk of stroke in patients getting Lucentis treatment.

ref: Review of Ophthalmology